Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioNTech SE (BNTX) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and annual reports on Form 20-F. As a foreign private issuer listed on Nasdaq, BioNTech uses these filings to report financial results, material agreements, strategic transactions and key corporate presentations.
Through its 6-K filings, BioNTech has furnished quarterly financial statements and operating reviews, detailing revenues from its COVID-19 vaccine franchise, collaboration income and research and development spending related to its oncology and mRNA programs. Other 6-Ks incorporate press releases and presentations covering topics such as third quarter results, R&D and AI-focused events, and strategic business updates presented at investor conferences.
Regulatory filings also document major corporate transactions and collaborations. For example, BioNTech has filed 6-Ks that attach press releases on its public exchange offer for all outstanding shares of CureVac N.V. and the subsequent completion of that acquisition, as well as a detailed description of the amended and restated global co-development and co-commercialization agreement with Bristol Myers Squibb for the bispecific antibody pumitamig (BNT327/BMS986545). These documents outline development responsibilities, cost-sharing, profit and loss sharing and intellectual property licensing arrangements.
Investors can use this page to review filings related to clinical and strategic milestones, including R&D day presentations, AI strategy updates and oncology pipeline overviews that are furnished as exhibits to Form 6-K. Stock Titan enhances access to these materials by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the key points of lengthy documents such as financial reports, collaboration agreements and transaction-related disclosures.
For those researching BNTX stock, the filings page is a resource for understanding how BioNTech describes its business, reports its financial performance, and records significant agreements and acquisitions in the official SEC record.
BioNTech SE launched an exchange offer to acquire all outstanding CureVac shares by issuing 15,061,575 newly registered ADSs of BioNTech in the UK offer described here. Holders of CureVac shares will receive BioNTech ADSs based on an exchange ratio equal to $5.4641 divided by the BioNTech ADS VWAP, with a collar fixing the ratio at 0.04318 if VWAP is ≥ $126.55 and at 0.06476 if VWAP is ≤ $84.37. Fractional ADSs will be paid in cash based on the VWAP.
The offer commences on October 21, 2025 and initially expires at 9:00 a.m. New York time on December 3, 2025, followed by a subsequent offering period of not less than 10 business days. Closing is subject to conditions including at least 80% of CureVac share capital tendered (reducible to 75% in certain circumstances), required regulatory approvals, no specified material adverse effects, and CureVac shareholder resolutions. BioNTech will not receive cash proceeds from the offer.
Support agreements covering approximately 57% of CureVac shares have been signed. As context, BioNTech notes an expected decrease in BioNTech shareholders’ aggregate percentage ownership of between 5.9% and 4.0%, depending on the final exchange ratio.
BioNTech SE filed a Form 6‑K to inform investors that on October 1, 2025 it hosted its second AI Day together with its artificial intelligence company InstaDeep Ltd. This event is part of BioNTech’s “Innovation Series” and provided an overview of its AI strategy, its AI capabilities, and how AI is applied across BioNTech’s product pipeline and internal processes.
The related investor presentation, offering more detail on these AI initiatives, is furnished as Exhibit 99.1 to the report.
BioNTech SE filed a Form 6-K noting that it and Bristol Myers Squibb have presented interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) in extensive-stage small cell lung cancer. The investigational bispecific antibody targets PD-L1 and VEGF-A and is being evaluated in combination with chemotherapy. According to the attached press release description, the interim Phase 2 data show encouraging antitumor activity in this patient population.
BioNTech entered a materially significant collaboration with Bristol-Myers Squibb to develop and commercialize the investigational bispecific antibody BNT327. Under the amended and restated agreement, BMS will pay $1.5 billion upfront plus $2.0 billion in non-contingent anniversary payments through 2028, and BioNTech is eligible for up to $7.6 billion in additional milestones. The parties will equally share global profits and losses and will generally split development costs equally, with adjusted sharing when one party contributes proprietary assets to a combination trial. BioNTech will initially supply clinical material and lead manufacturing transfer to BMS, after which BMS will assume commercial supply while BioNTech retains the right to supply a percentage of commercial product. Co-exclusive IP licenses and joint governance structures for development and commercialization are established.
BioNTech SE (BNTX) Form 144 notice reports a proposed sale of 500,000 American Depositary Shares through Goldman Sachs & Co. LLC with an approximate aggregate market value of $56,230,000 and an approximate sale date of 09/05/2025. The ADS class shows 237,725,735 shares outstanding. The filing states the 500,000 ADS were originally acquired in a private placement on 01/05/2018 from BioNTech SE and paid in cash. The notice also lists multiple prior sales by AT Impf GmbH during the past three months, including transactions on 06/05/2025 (50,000 ADS), 07/10/2025 (40,000 ADS), and several July 2025 dates down to 4,500 and 500 ADS, each with reported gross proceeds. The filer certifies no undisclosed material adverse information.
BioNTech SE reported that a pivotal Phase 3 trial of its antibody-drug conjugate candidate trastuzumab pamirtecan (BNT323/DB-1303), developed with Duality Biologics, met its primary goal. The study, conducted by DualityBio in China, compares BNT323/DB-1303 with trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have already received trastuzumab and a taxane-based chemotherapy.
At a pre-specified interim analysis, the trial achieved its primary endpoint of progression free survival, meaning patients on BNT323/DB-1303 lived longer without their cancer worsening than those on the comparator. A detailed press release with more information on the results is referenced as an exhibit to this report.
BioNTech SE reports that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for its and Pfizer’s LP.8.1‑adapted monovalent COVID‑19 vaccine, COMIRNATY LP.8.1. The vaccine is now approved for adults aged 65 and older and for individuals aged 5 through 64 who have at least one underlying condition that puts them at high risk for severe COVID‑19. This expands use of the updated mRNA vaccine in key higher‑risk groups in the United States.
Form 144 filing for BioNTech SE (BNTX) shows a proposed sale of 1,774,837 American Depositary Shares representing ordinary shares, with an aggregate market value of $200,024,129.90. The sale is reported through Berenberg Capital Markets LLC on 08/15/2025 and the shares are listed on the Nasdaq Global Select. The filing discloses that the seller acquired the underlying ordinary shares via stock option exercises on 08/09/2024 (918,651 shares) and 11/21/2022 (856,186 shares). The filing reports no sales in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 filed for BioNTech SE (BNTX) reporting a proposed sale of 185,001 American Depositary Shares (ADS) representing ordinary shares. The broker listed is Berenberg Capital Markets LLC with an approximate sale date of 08/15/2025 on Nasdaq Global Select. The aggregate market value of the proposed sale is reported as $20,849,612.70 and the number of shares outstanding is listed as 240,398,724. The securities were acquired on 11/21/2022 through a stock option exercise from BioNTech SE. The filer reports no securities sold in the past three months and includes the standard certification that the seller is not aware of undisclosed material adverse information.
BioNTech announced settlement arrangements resolving U.S. patent litigation with CureVac and related arrangements with GSK and Pfizer. The parties agreed to dismiss U.S. patent claims and BioNTech received a non-exclusive U.S. license (with sublicensing rights) to make, use, sell and import mRNA vaccines for COVID-19 and influenza developed with Pfizer. The deal creates royalty and cash obligations: BioNTech will pay $370 million to GSK and $370 million to CureVac under specified triggers, plus a 1% royalty on U.S. sales of licensed products to each of GSK and CureVac effective January 1, 2025.
Subject to closing of BioNTech’s planned acquisition of CureVac, the company will obtain worldwide non-exclusive licenses, the parties must dismiss non-U.S. claims, BioNTech will pay an additional $130 million to GSK upon certain later conditions, and Pfizer agreed to reimburse BioNTech $80 million plus half of claimed GSK royalties from January 1, 2025 for COVID-19 mRNA products. The company disclaims any admission of liability and highlights transactional and regulatory risks.